PTPN23-dependent activation of PI3KC2α is a therapeutic vulnerability of BRAF-mutant cancers

Area of Science:

• Oncology
• Molecular Biology
• Biochemistry

Background:

• BRAF mutations are key drivers in various cancers, particularly melanoma.
• BRAF inhibitors are effective but often face intrinsic or acquired resistance.
• Identifying alternative therapeutic targets is crucial for overcoming treatment resistance.

Purpose of the Study:

• To identify novel therapeutic targets in BRAF-mutant cancers.
• To investigate the role of non-receptor-type protein tyrosine phosphatase 23 (PTPN23) in BRAF-mutant melanoma.
• To elucidate the signaling pathway regulated by PTPN23.

Main Methods:

• Gene silencing of PTPN23 in cancer cell lines.
• Analysis of protein phosphorylation and signaling pathway activation (WNK3, PI3KC2α, AKT2).
• In vitro and in vivo studies using genetic and pharmacological targeting.
• Melanocyte-specific knockout models for BRAFV600E-driven melanomagenesis.

Main Results:

• Silencing PTPN23 selectively eliminates BRAF-mutant melanoma cells.
• PTPN23 activates PI3KC2α via WNK3-mediated phosphorylation, enhancing its activity.
• The PTPN23-PI3KC2α-AKT2 axis promotes cancer cell survival.
• Targeting this axis, alone or with BRAF inhibitors, inhibits tumor growth.
• PTPN23 knockout suppresses BRAFV600E-driven melanomagenesis.

Conclusions:

• PTPN23 is a critical regulator of the PI3KC2α-AKT2 pathway in BRAF-mutant cancers.
• Targeting PTPN23 represents a novel and effective therapeutic strategy for BRAF-mutant melanoma and other cancers.
• This approach can overcome resistance to existing BRAF inhibitor therapies.